Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW ...

Keytruda plus platinum-based chemotherapy was found to be both safe and efficacious in treating penile squamous cell carcinoma (PSCC), according to findings from the phase 2 HERCULES trial presented ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose ...

The main market opportunities for PD-1 Resistant Head and Neck Cancer include developing combination therapies and next-gen ...

Janux Therapeutics, Inc. (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell ...

Bicara Therapeutics announced the publication of an abstract with early data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa ...

Regeneron Pharmaceuticals’ Libtayo (cemiplimab) has received approval from the European Commission for the adjuvant treatment ...

Alcohol and tobacco use are two of the most important risk factors for head and neck cancers. However, a large portion of new head and neck diagnoses are being driven by cancer-causing types of human ...

New research links tattoos to increased melanoma skin cancer risk Tattoos might seem like harmless self-expression, but could they secretly raise your ...

Bicara completed its Initial Public Offering ("IPO") on September 16th, 2024, raising ~$362m via the issuance of ~20.13m ...

Vietnam's Ministry of Health has given the green light to the Russian-made cancer drug Pembroria to provide patients with a ...